Why Is Cue Biopharma Stock Up Today?

Cue Biopharma (CUE) stock rocketed higher on Friday after the clinical-stage biopharmaceutical company announced a $30 million private placement. The company has entered into a securities purchase agreement with certain accredited investors for the private placement. This financing is expected to close on May 4, 2026.

Under the terms of the securities purchase agreement, Cue Biopharma will sell up to 2,727,272 shares of CUE and warrants to purchase another 1,363,636 shares to the accredited investors. The shares will be sold for $11 each, while the warrants will have an exercise price that matches the share price. There’s also an option for pre-funded warrants under certain conditions.

Cue Biopharma said that it will use the funds from the private placement to advance the company’s clinical pipeline, including the acquisition and development of Ascendant-221, working capital, and other general corporate purposes. The company’s main focus is the development of autoimmune and inflammatory disease treatments that selectively engage and modulate disease-specific T cells.

Cue Biopharma Stock Movement Today

Cue Biopharma stock was up 92.33% in premarket trading on Friday, following a 13.38% rally on Thursday. The stock has also increased 60.88% year-to-date but was down 34.72% over the past 12 months.

CUE stock experienced heavy trading today as some 4.5 million shares changed hands, compared to a three-month average daily trading volume of about 1.9 million shares.

Is Cue Biopharma Stock a Buy, Sell, or Hold?

Turning to Wall Street, traditional analyst coverage of Cue Biopharma is lacking. Fortunately, TipRanks’ AI analyst Spark has it covered. Spark rates CUE stock as Neutral with a $13.50 price target. It cites “weak financial performance, driven by persistent losses and negative free cash flow” as reasons for this stance.